Taken together, these results suggest that JQ1+NSC combination therapy exerts significant anti-cancer effects in breast tumorigenesis and highlights the importance of combined inhibition of BRD4-RAC1 signaling in breast cancer development and progression. This evidence concerns the gene BRD4 and cancer.